GAMMAPLEX Drug Profile

Summary for Tradename: GAMMAPLEX

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for GAMMAPLEX

Recent Clinical Trials for GAMMAPLEX

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Isaac Melamed	Phase 4
Bio Products Laboratory	Phase 4

See all GAMMAPLEX clinical trials

Pharmacology for GAMMAPLEX

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for GAMMAPLEX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for GAMMAPLEX Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for GAMMAPLEX Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bio Products Laboratory	GAMMAPLEX	immune globulin intravenous (human)	Injection	125329	10,001,489	2033-08-19	Patent claims search
Bio Products Laboratory	GAMMAPLEX	immune globulin intravenous (human)	Injection	125329	10,011,660	2033-04-17	Patent claims search
Bio Products Laboratory	GAMMAPLEX	immune globulin intravenous (human)	Injection	125329	10,016,338	2036-12-20	Patent claims search

Market Dynamics and Financial Trajectory for GAMMAPLEX

Last updated: April 14, 2026

What is GAMMAPLEX?

GAMMAPLEX (Immune Globulin Infusion) is a human normal immunoglobulin G (IgG) intravenous product used primarily for immunodeficiency diseases, autoimmune disorders, and certain neurologic conditions. It is produced from pooled human plasma and is marketed by Kedrion Biopharma, with other manufacturers also involved in production and distribution.

Market Size and Growth Drivers

Global Market Overview

The global immunoglobulin market was valued at approximately USD 10.9 billion in 2022 and is projected to reach USD 16.2 billion by 2028, registering a Compound Annual Growth Rate (CAGR) of around 6.0% from 2023 to 2028 [1].

Key Growth Drivers

• Rising prevalence of primary immunodeficiency diseases (PI), with prevalence estimates of 1 in 10,000 to 15,000 live births globally.
• Increasing approvals for new indications, such as neurological and autoimmune disorders.
• Expanding use in developed markets driven by advanced healthcare infrastructure.
• Emergence of subcutaneous formulations, offering home-based administration.

Market Segments and Indications

The principal segments include:

• Primary immunodeficiency (PI): 55%
• Autoimmune diseases (e.g., ITP, multifocal motor neuropathy): 25%
• Secondary immunodeficiency (e.g., cancer-related): 20%

Geographic Distribution

North America represented 54% of the market in 2022, owing to high diagnosis rates, reimbursement policies, and established supply chains. Europe accounts for roughly 27%, with Asia-Pacific growing rapidly but still comprising 11% of market revenue.

Competition and Market Share

Major Players

• CSL Behring: Holds the largest share, with products like Privigen and Hizentra.
• Grifols: Markets Gammagard and other formulations.
• Takeda: Offers multiple IgG products.
• Kedrion: Markets GAMMAPLEX.

Market Share Distribution

Company	Approximate Market Share (2022)
CSL Behring	45%
Grifols	25%
Takeda	15%
Kedrion	8%
Others	7%

GAMMAPLEX holds an estimated 8% of the global immunoglobulin market, with regional dominance in select markets.

Regulatory and Pricing Environment

Regulatory Approvals

GAMMAPLEX has approval for use in various indications, including primary immunodeficiency and idiopathic thrombocytopenic purpura (ITP). Regulatory bodies such as the FDA and EMA have approved multiple formulations, including intravenous (IV) and subcutaneous (SC) options.

Pricing Dynamics

Prices for immunoglobulin products vary geographically:

• North America: USD 70–USD 200 per gram.
• Europe: EUR 50–EUR 150 per gram.
• Asia-Pacific: Prices are generally lower but increasing with expanded indications.

Reimbursement policies impact volume sales significantly. Cost containment and alternatives like biosimilars exert downward pressure on prices.

Financial Projections

Revenue Trends

Historically, GAMMAPLEX's revenue growth has aligned with the overall immunoglobulin market, driven by steady demand and expansion into new indications.

• 2022: Estimated USD 150 million in sales.
• 2025: Projected approximately USD 200–USD 220 million, assuming a CAGR of 8%, supported by increased adoption and new indications.
• 2028: Estimated USD 280 million with continued market expansion and potential new formulations.

Cost Considerations

Manufacturing costs include plasma collection, purification, and quality assurance. Supply chain disruptions, plasma availability, and regulatory compliance influence margins.

Investment and R&D

Investments in developing novel formulations, such as recombinant IgG or enhanced subcutaneous variants, aim to capture market share. Clinical trials for new indications remain critical to product value expansion.

Trends Shaping Future Market Performance

• Growth in autoimmune and neurological indications.
• Adoption of subcutaneous formulations enabling home therapy.
• Potential entry of biosimilars reducing prices and increasing accessibility.
• Advances in manufacturing, including recombinant approaches, which could alter supply dynamics.

Key Takeaways

• The immunoglobulin market is expanding at a CAGR of 6–8%, with GAMMAPLEX capturing roughly 8% of the global share.
• Drivers include rising disease prevalence, new indications, and formulation innovations.
• Competitive landscape centers on CSL Behring and Grifols, with Kedrion positioned as a niche provider.
• Pricing varies geographically but generally remains high, impacted by reimbursement policies.
• Revenue growth for GAMMAPLEX hinges on expanding indications, formulations, and market penetration in Asia-Pacific.

FAQs

Q1: How does GAMMAPLEX compare to other immunoglobulin products?
A1: GAMMAPLEX is an intravenous IgG product with indications similar to those of Privigen and Gammagard, offering comparable efficacy. Its differentiating factors include formulation stability and regional availability.

Q2: What are the primary regulatory barriers for GAMMAPLEX?
A2: Barriers include meeting regional safety and efficacy standards, obtaining approval for new indications, and regulatory variability between jurisdictions.

Q3: How will biosimilars impact GAMMAPLEX’s market share?
A3: Biosimilars could reduce prices and increase volume, potentially eroding market share if they demonstrate bioequivalence and gain regulatory approval.

Q4: What is the outlook for subcutaneous formulations of GAMMAPLEX?
A4: Subcutaneous options are increasingly adopted, offering convenience and reduced infusion times, which could expand the patient base and revenue.

Q5: Are there emerging technologies that could disrupt GAMMAPLEX’s market?
A5: Recombinant IgG production and plasma-free biologics are under development, promising supply chain resilience and cost reduction but are not yet widely commercialized.

---

References

[1] Grand View Research. (2023). Immunoglobulin Market Size, Share & Trends Analysis Report.